Dr. Reddy's Reports Significant Q3 Profit Decline Amidst Revenue Growth and Ongoing Legal/Regulatory Scrutiny

summarizeSummary

Dr. Reddy's Laboratories reported a 15% decline in Q3 net profit and a 24% drop in operating profit, despite a 4% revenue increase, while facing ongoing material legal and regulatory challenges.

check_boxKey Events

• Q3 Profitability Decline

  Net profit decreased by 15% to Rs. 11,896 million and operating profit by 24% to Rs. 14,238 million for the three months ended December 31, 2025, compared to the prior year, despite a 4% revenue increase.

• Gross Margin Contraction

  Gross profit margin for the Global Generics segment decreased to 57.4% from 61.3%, and for the PSAI segment to 17.3% from 28.6% for the quarter.

• Ongoing FCPA Investigation

  The company continues to engage with the SEC and DOJ regarding an anonymous complaint alleging improper payments, with outcomes and liabilities currently unascertainable.

• Significant Antitrust Litigations

  Multiple U.S. antitrust multi-district litigations and a Canadian class action allege price-fixing and market allocation, with potential liabilities being unascertainable.

auto_awesomeAnalysis

Dr. Reddy's Laboratories reported a notable decline in profitability for the quarter ended December 31, 2025, with net profit decreasing by 15% and operating profit by 24% year-over-year, despite a 4% increase in revenues. This was primarily driven by a contraction in gross profit margins across both Global Generics and Pharmaceutical Services and Active Ingredients (PSAI) segments, coupled with increased selling, general, and administrative expenses, partly due to an incremental Rs. 1,170 million cost from new Indian Labour Codes. The company also faces significant, ongoing legal and regulatory risks, including an internal investigation into alleged improper payments (FCPA), multiple U.S. antitrust multi-district litigations, a Canadian class action, and the Revlimid® antitrust litigation, for which potential liabilities remain unascertainable. While some U.S. FDA inspections resulted in positive Voluntary Action Indicated (VAI) classifications, a Post Application Action Letter (PAAL) was received for the Biologics facility in Hyderabad, indicating continued regulatory scrutiny.